Semaglutide — Research Overview

Also known as: Ozempic, Wegovy, Rybelsus

A synthetic GLP-1 receptor agonist with a modified fatty acid chain enabling once-weekly subcutaneous administration or oral delivery. FDA-approved under brand names Ozempic (diabetes) and Wegovy (weight management). Among the most studied peptide-based drugs in history, studied for appetite suppression, glucose regulation, cardiometabolic improvement, and body weight reduction.

Back to Peptide Encyclopedia